These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 21568886)

  • 1. Aluminum vaccine adjuvants: are they safe?
    Tomljenovic L; Shaw CA
    Curr Med Chem; 2011; 18(17):2630-7. PubMed ID: 21568886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are there negative CNS impacts of aluminum adjuvants used in vaccines and immunotherapy?
    Shaw CA; Li D; Tomljenovic L
    Immunotherapy; 2014; 6(10):1055-71. PubMed ID: 25428645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical analysis of reference studies on the toxicokinetics of aluminum-based adjuvants.
    Masson JD; Crépeaux G; Authier FJ; Exley C; Gherardi RK
    J Inorg Biochem; 2018 Apr; 181():87-95. PubMed ID: 29307441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations.
    Tomljenovic L; Shaw CA
    Lupus; 2012 Feb; 21(2):223-30. PubMed ID: 22235057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aluminum as an adjuvant in vaccines and post-vaccine reactions].
    Fiejka M; Aleksandrowicz J
    Rocz Panstw Zakl Hig; 1993; 44(1):73-80. PubMed ID: 8235346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism?
    Tomljenovic L; Shaw CA
    J Inorg Biochem; 2011 Nov; 105(11):1489-99. PubMed ID: 22099159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aluminium adjuvant exposure through vaccines in France in 2018].
    Angrand L; Elnar AA; Authier FJ; Gherardi RK; Crépeaux G
    Ann Pharm Fr; 2020 Mar; 78(2):111-128. PubMed ID: 32081303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reviewing the association between aluminum adjuvants in the vaccines and autism spectrum disorder.
    Boretti A
    J Trace Elem Med Biol; 2021 Jul; 66():126764. PubMed ID: 33930617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cumulative and episodic vaccine aluminum exposure in a population-based cohort of young children.
    Glanz JM; Newcomer SR; Daley MF; McClure DL; Baxter RP; Jackson ML; Naleway AL; Lugg MM; DeStefano F
    Vaccine; 2015 Nov; 33(48):6736-44. PubMed ID: 26518400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aluminum toxicokinetics regarding infant diet and vaccinations.
    Keith LS; Jones DE; Chou CH
    Vaccine; 2002 May; 20 Suppl 3():S13-7. PubMed ID: 12184359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In process].
    Kreutzkamp B
    Med Monatsschr Pharm; 2016 Oct; 39(10):447-8. PubMed ID: 29979546
    [No Abstract]   [Full Text] [Related]  

  • 12. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination.
    Mitkus RJ; King DB; Hess MA; Forshee RA; Walderhaug MO
    Vaccine; 2011 Nov; 29(51):9538-43. PubMed ID: 22001122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aluminum in vaccines: Does it create a safety problem?
    Principi N; Esposito S
    Vaccine; 2018 Sep; 36(39):5825-5831. PubMed ID: 30139653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aluminum-containing vaccine associated adverse events: role of route of administration and gender.
    Pittman PR
    Vaccine; 2002 May; 20 Suppl 3():S48-50. PubMed ID: 12184365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal administration of aluminium-based adjuvants produces severe transient systemic adverse events in mice.
    Freiberger SN; Leuthard DS; Duda A; Contassot E; Thallmair M; Kündig TM; Johansen P
    Eur J Pharm Sci; 2018 Mar; 115():362-368. PubMed ID: 29410031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Itching nodules and hypersensitivity to aluminium after the use of adsorbed vaccines from SSI.
    Thierry-Carstensen B; Stellfeld M
    Vaccine; 2004 May; 22(15-16):1845. PubMed ID: 15121293
    [No Abstract]   [Full Text] [Related]  

  • 17. Aluminum adjuvants of vaccines injected into the muscle: Normal fate, pathology and associated disease.
    Gherardi RK; Aouizerate J; Cadusseau J; Yara S; Authier FJ
    Morphologie; 2016 Jun; 100(329):85-94. PubMed ID: 26948677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myalgia and chronic fatigue syndrome following immunization: macrophagic myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune system.
    Gherardi RK; Crépeaux G; Authier FJ
    Autoimmun Rev; 2019 Jul; 18(7):691-705. PubMed ID: 31059838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public health. Aluminum is put on trial as a vaccine booster.
    Malakoff D
    Science; 2000 May; 288(5470):1323-4. PubMed ID: 10847840
    [No Abstract]   [Full Text] [Related]  

  • 20. Aluminum in Vaccines: Addressing Parents' Concerns.
    Fernandez S
    Pediatr Ann; 2016 Jul; 45(7):e231-3. PubMed ID: 27403668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.